ViatrisHAM:VIA +0.06%60 Pretax Margin % is -7.03% as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.62 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 952 Drug Manufacturers companies, Viatris ranks worse than 73.74% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Viatris's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-214 Mil. Viatris's Revenue for the
three
months ended in Mar. 2026 was €3,042 Mil. Therefore, Viatris's pretax margin for the quarter that ended in Mar. 2026 was -7.03%.
The historical rank and industry rank for Viatris's Pretax Margin % or its related term are showing as below:
HAM:VIA'
s Pretax Margin % Range Over the Past 10 Years
Min: -25.63 Med: 1.21 Max: 17.3
Current: -5.6
HAM:VIA's Pretax Margin % is ranked worse than 73.74% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs HAM:VIA: -5.60
Viatris (HAM:VIA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Viatris Pretax Margin % Related Terms
Viatris Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Viatris's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Viatris's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Pretax Margin % of -7.03% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Viatris and its competitors. According to the industry distribution chart, Viatris ranks #702 out of 952 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is Viatris' Pretax Margin % too high?
Viatris' current Pretax Margin % is -7.03%. Based on the distribution chart, Viatris ranks #702 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Pretax Margin % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #702 out of 952 companies for Pretax Margin %. This places Viatris in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Pretax Margin % is -7.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.62, compared to a current price of €14.26 — trading 48.3% above its estimated fair value. The current Pretax Margin % is -7.03%. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Pretax Margin % is -7.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 48.3% above its estimated GF Value™ of €9.62.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Pretax Margin %: -7.03%
GF Value™: €9.62 vs. price of €14.26 (48.3% above fair value)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for HAM:VIA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
